Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
VTYX.US
id: 1125

Ventyx Biosciences (VTYX) Lead Product Candidate Failure Case

S.D. California
Court
3:24-cv-00415
Case number
21 Oct 2021
Class period Start
06 Nov 2023
Class period End
30 Apr 2024
Lead Plaintiff motion deadline
  • $VTYX stockholder filed a claim vs. Ventyx Biosciences for purportedly overpromising the potential success of plaque psoriasis candidate during the IPO in 2021.
  • In November 2022, disappointing Phase 2 SERENITY Trial results caused $VTYX to fall 80%, losing $672 million in shareholder value.
On November 6, 2023, Ventyx Biosciences (VTYX) announced the results of the Phase 2 SERENITY Trial, disclosing that "although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis."

Based on these results, Ventyx announced that it "will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately" and "terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis."
On this news, $VTYX fell 80.6% and lost over $672 million of its market capitalization, seriously damaging investors.

Then, on November 22, 2023, Ventyx disclosed that its President & CMO, William J. Sandborn, would cease to serve in those roles.

$VTYX is trading at $8.5 per share, well below the $16 IPO price.

Considering all the facts, investors have reasons to suspect Ventyx and its Leader of overpromising the potential success of the lead product candidate during the IPO in 2021.

The first $VTYX stockholder filed a claim vs. Ventyx over misleading IPO in S.D. California court.
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Shareholder
Investment Bank
Security Type
Stocks
Trade Direction
Long
Shock Event Date
07 November 2023
Filing date
01 March 2024
Lead Plaintiff Deadline
30 April 2024
Collecting participants…

Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product can...

    Ticker
    VTYX.US
    ISIN
    US92332V1070
    CIK
    1851194
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    12790 El Camino Real, San Diego, CA, United States, 92130